Santagata Sara, Ieranò Caterina, Trotta Anna Maria, Capiluongo Anna, Auletta Federica, Guardascione Giuseppe, Scala Stefania
Research Department, Microenvironment Molecular Targets, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", Napoli, Italy.
Front Oncol. 2021 Apr 15;11:591386. doi: 10.3389/fonc.2021.591386. eCollection 2021.
The chemokine receptor 4 (CXCR4) and 7 (CXCR7) are G-protein-coupled receptors (GPCRs) activated through their shared ligand CXCL12 in multiple human cancers. They play a key role in the tumor/tumor microenvironment (TME) promoting tumor progression, targeting cell proliferation and migration, while orchestrating the recruitment of immune and stromal cells within the TME. CXCL12 excludes T cells from TME through a concentration gradient that inhibits immunoactive cells access and promotes tumor vascularization. Thus, dual CXCR4/CXCR7 inhibition will target different cancer components. CXCR4/CXCR7 antagonism should prevent the development of metastases by interfering with tumor cell growth, migration and chemotaxis and favoring the frequency of T cells in TME. Herein, we discuss the current understanding on the role of CXCL12/CXCR4/CXCR7 cross-talk in tumor progression and immune cells recruitment providing support for a combined CXCR4/CXCR7 targeting therapy. In addition, we consider emerging approaches that coordinately target both immune checkpoints and CXCL12/CXCR4/CXCR7 axis.
趋化因子受体4(CXCR4)和7(CXCR7)是G蛋白偶联受体(GPCR),在多种人类癌症中通过其共同配体CXCL12被激活。它们在肿瘤/肿瘤微环境(TME)中发挥关键作用,促进肿瘤进展,靶向细胞增殖和迁移,同时协调TME内免疫细胞和基质细胞的募集。CXCL12通过浓度梯度将T细胞排除在TME之外,该浓度梯度抑制免疫活性细胞的进入并促进肿瘤血管生成。因此,双重CXCR4/CXCR7抑制将针对不同的癌症成分。CXCR4/CXCR7拮抗作用应通过干扰肿瘤细胞的生长、迁移和趋化性,并增加TME中T细胞的频率来预防转移的发生。在此,我们讨论了目前对CXCL12/CXCR4/CXCR7相互作用在肿瘤进展和免疫细胞募集中作用的理解,为联合CXCR4/CXCR7靶向治疗提供支持。此外,我们还考虑了同时靶向免疫检查点和CXCL12/CXCR4/CXCR7轴的新兴方法。